Q190706 (Q190706): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiM...) |
(Changed label, description and/or aliases in 1 language: remove_english_label) |
||
| label / en | label / en | ||
Revision as of 09:29, 13 October 2020
Project in France financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in France financed by DG Regio |
Statements
10,211,026.83 Euro
0 references
13,614,711.32 Euro
0 references
75.0 percent
0 references
1 December 2017
0 references
30 November 2021
0 references
Université de Franche-Comté
0 references
Q2537920 (Deleted Item)
0 references
47°14'23.03"N, 6°0'44.14"E
0 references
25030
0 references
Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
0 references
Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English)
13 October 2020
0 references
0 references
Identifiers
10341
0 references
4607
0 references